Chunghwa Chemical Synthesis & Biotech Co (TPE:1762) Revenue: NT$934.3 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TPE:1762 Chunghwa Chemical Synthesis & Biotech Co Ltd TPE:1762
60 GF Score
Price NT$35.00
GF Value NT$40.11
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Chunghwa Chemical Synthesis & Biotech Co Revenue?

Chunghwa Chemical Synthesis & Biotech Co TPE:1762 -0.14% 60 Revenue is NT$934.3 Mil as of Jun. 2026. GuruFocus rates TPE:1762 with a GF Score™ of 60/100 and a GF Value™ of NT$40.11 (Modestly Undervalued). The stock has 3 warning signs investors should review.

Chunghwa Chemical Synthesis & Biotech Co's revenue for the three months ended in Jun. 2026 was NT$305.2 Mil. Its revenue for the trailing twelve months (TTM) ended in Jun. 2026 was NT$934.3 Mil. Chunghwa Chemical Synthesis & Biotech Co's Revenue per Share for the three months ended in Jun. 2026 was NT$5.51. Its Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2026 was NT$16.89.

Warning Sign:

Chunghwa Chemical Synthesis & Biotech Co Ltd revenue per share has been in decline for the last 5 years.

During the past 12 months, the average Revenue per Share Growth Rate of Chunghwa Chemical Synthesis & Biotech Co was -0.60% per year. During the past 3 years, the average Revenue per Share Growth Rate was -18.70% per year. During the past 5 years, the average Revenue per Share Growth Rate was -4.60% per year. During the past 10 years, the average Revenue per Share Growth Rate was 5.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.

During the past 13 years, Chunghwa Chemical Synthesis & Biotech Co's highest 3-Year average Revenue per Share Growth Rate was 23.80% per year. The lowest was -18.70% per year. And the median was 0.10% per year.


Chunghwa Chemical Synthesis & Biotech Co  (TPE:1762) Revenue Explanation

In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.

Peter Lynch categorized companies according to their revenue growth:


Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:
Stalwart: 10% < 10-Year Revenue Growth Rate < 20%:
Fast Grower: 10-Year Revenue Growth Rate > 20%:

His favorite companies are stalwart, those growing between 10-20% a year.

Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.


Be Aware

Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.


Chunghwa Chemical Synthesis & Biotech Co Revenue Related Terms


Chunghwa Chemical Synthesis & Biotech Co Revenue Historical Data

* Premium members only.

The historical data trend for Chunghwa Chemical Synthesis & Biotech Co's Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Chunghwa Chemical Synthesis & Biotech Co Revenue Chart

Chunghwa Chemical Synthesis & Biotech Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,934.70 2,117.14 2,086.44 1,347.38 804.88

Chunghwa Chemical Synthesis & Biotech Co Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 344.04 154.47 113.42 361.23 305.18

TPE:1762 vs VRTX, REGN, RVMD: Revenue Comparison

For the Biotechnology subindustry, Chunghwa Chemical Synthesis & Biotech Co's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Chunghwa Chemical Synthesis & Biotech Co Revenue vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Chunghwa Chemical Synthesis & Biotech Co's Revenue distribution charts can be found below:

* The bar in red indicates where Chunghwa Chemical Synthesis & Biotech Co's Revenue falls into.


TPE:1762
60GF Score
Chunghwa Chemical Synthesis & Biotech Co Ltd TPE:1762
Revenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Chunghwa Chemical Synthesis & Biotech Co Revenue Calculation

Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.

Revenue for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$934.3 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Revenue →
What does a Revenue of NT$934.3 Mil mean?
Chunghwa Chemical Synthesis & Biotech Co (TPE:1762) has a Revenue of NT$934.3 Mil as of Jun. 2026. Revenue is the total amount a company generates as sales through its operations. View historical data on Chunghwa Chemical Synthesis & Biotech Co and its competitors.
Is Chunghwa Chemical Synthesis & Biotech Co's Revenue too high?
Chunghwa Chemical Synthesis & Biotech Co's current Revenue is NT$934.3 Mil. Overall, Chunghwa Chemical Synthesis & Biotech Co has a GF Score™ of 60/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Chunghwa Chemical Synthesis & Biotech Co's Revenue compare to VRTX and REGN?
Chunghwa Chemical Synthesis & Biotech Co's Revenue of NT$934.3 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue for a Biotechnology company?
A good Revenue depends on the Biotechnology industry context. However, Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue mean?
A high Revenue can signal that a stock is expensive relative to its fundamentals. Revenue is the total amount a company generates as sales through its operations. View historical data on Chunghwa Chemical Synthesis & Biotech Co and its competitors. Chunghwa Chemical Synthesis & Biotech Co's current Revenue is NT$934.3 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chunghwa Chemical Synthesis & Biotech Co stock overvalued right now?
Based on GuruFocus' analysis, Chunghwa Chemical Synthesis & Biotech Co (TPE:1762) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$40.11, compared to a current price of NT$35.00 — trading 12.7% below its estimated fair value. The current Revenue is NT$934.3 Mil. Chunghwa Chemical Synthesis & Biotech Co's overall GF Score™ is 60/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue calculated?
Revenue is calculated from a company's financial statements. For Chunghwa Chemical Synthesis & Biotech Co (TPE:1762), the current Revenue is NT$934.3 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Chunghwa Chemical Synthesis & Biotech Co (TPE:1762) Overvalued in 2026?

Based on GuruFocus' analysis, Chunghwa Chemical Synthesis & Biotech Co stock appears to be undervalued. The current stock price of NT$35.00 is trading 12.7% below its estimated GF Value™ of NT$40.11. GuruFocus considers Chunghwa Chemical Synthesis & Biotech Co to be Modestly Undervalued.

Key valuation signals for TPE:1762:

  • Revenue: NT$934.3 Mil
  • GF Value™: NT$40.11 vs. price of NT$35.00 (12.7% below fair value)
  • GF Score™: 60/100 with 3 warning signs

No single metric tells the full story. See the TPE:1762 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Chunghwa Chemical Synthesis & Biotech Co Business Description

Address No. 1, Dongxing Street, Shulin District, Taipei, TWN
Chunghwa Chemical Synthesis & Biotech Co Ltd is engaged in the research, development, manufacturing, and sales of pharmaceutical products. Geographically, it derives a majority of its revenue from the United States and also has a presence in Taiwan. Its product portfolio comprises pain management, antifungal, immunosuppressant, oncology, Cardiovascular, Peptide Drugs, and Others.
60GF Score

Get the complete analysis for TPE:1762

Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$35.00
Price
NT$40.11
GF Value